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Aims Rupture-prone atherosclerotic plaques are characterized by inflammation and a large necrotic core. Inflammation is
linked to high metabolic activity. Advanced glycation endproducts (AGEs) and their major precursor methylglyoxal
are formed during high metabolic activity and can have detrimental effects on cellular function and may induce cell
death. Therefore, we investigated whether plaque AGEs are increased in human carotid rupture-prone plaques and
are associated with plaque inflammation and necrotic core formation.
Methods
and results
The protein-bound major methylglyoxal-derived AGE 5-hydro-5-methylimidazolone (MG-H1) and N1-
(carboxymethyl)lysine (CML) were measured in human carotid endarterectomy specimens (n ¼ 75) with tandem
mass spectrometry. MG-H1 and CML levels were associated with rupture-prone plaques, increased protein levels of
the inflammatory mediators IL-8 and MCP-1 and with higher MMP-9 activity. Immunohistochemistry showed that
AGEs accumulated predominantly in macrophages surrounding the necrotic core and co-localized with cleaved
caspase-3. Intra-plaque comparison revealed that glyoxalase-1 (GLO-1), the major methylglyoxal-detoxifying enzyme,
mRNAwas decreased (213%, P , 0.05) in ruptured compared with stable plaque segments. In line, in U937 monoctyes,
we found reduced (GLO-1) activity (238%,P , 0.05) and increased MGO(346%, P , 0.05)production after stimulation
with the inflammatory mediator TNF. Direct incubation with methylglyoxal increased apoptosis up to two-fold.
Conclusion This is the first study showing that AGEs are associated with human rupture-prone plaques. Furthermore, this study sug-
gests a cascade linking inflammation, reduced GLO-1, methylglyoxal- and AGE-accumulation, and subsequent apoptosis.
Thereby, AGEs may act as mediators of the progression of stable to rupture-prone plaques, opening a window towards
novel treatments and biomarkers to treat cardiovascular diseases.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Atherosclerosis † Advanced glycation endproducts † Cell death † Glyoxalase † Macrophage † Plaque rupture
Introduction
Rupture of an atherosclerotic plaque and subsequent thrombosis is
the major cause of cardiovascular events such as heart attack and
stroke.1,2 The major histological components of rupture-prone plaques
are inflammation, macrophage infiltration, and a large necrotic core.3
Inflammation of the plaque is characterized by high metabolic ac-
tivity in macrophages, as characterized by high 18Fluor-deoxyglucose
* Corresponding author. Tel: +31 43 3882186, Fax: +31 43 3875006, Email: c.schalkwijk@maastrichtuniversity.nl
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2013. For permissions please email: journals.permissions@oup.com
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uptake,4 hypoxia,5 and oxidative stress.6 Advanced glycation endpro-
ducts (AGEs) area large familyof extensively sugar-modifiedproteins
which can be formed in plaques as a consequence of increased meta-
bolic activity.7 Indeed, we and others have demonstrated that AGEs, in-
cluding major AGE N1-(carboxymethyl)lysine (CML), are present in
atherosclerotic lesions.8–11 Moreover, animal studies have shown that
therapies decreasing AGEs attenuate atherosclerosis.12–14 Despite the
clear link between AGEs and atherosclerosis, their precise mechanism
of action remains largely unknown.
It is becoming apparent that especially intracellular sugars and their
derivatives can induce AGE formation, with the dicarbonyl methyl-
glyoxal (MGO) as the most reactive AGE precursor.15 MGO reacts
primarily with arginine residues to form the non-fluorescent AGE
5-hydro-5-methylimidazolone (MG-H1). MGO-derived AGEs have
been linkedtovascularcomplications,16generationof freeoxygenradi-
cals,17 and apoptosis.18,19 MGO can be detoxified by glyoxalase 1
(GLO-1), GLO-2 and reduced glutathione20 into D-lactate, thereby
preventing accumulation of MGO and MGO-derived AGEs. There-
fore, we hypothesized that reduced GLO-1 activity, production of
MGO, and subsequent AGEs may be a major factor contributing to
theassociationbetweenplaque inflammationandnecrotic core forma-
tion, which in turn may predispose plaques to rupture.
In rupture-prone plaques, i.e. plaques with an inflammatory ather-
omatous phenotype, we found higher plaque AGEs, which accumu-
lated in macrophages, and co-localized with cleaved caspase-3 and
hypoxia. Moreover, GLO-1 was decreased in ruptured plaques. In
line, we showed a direct role of MGO on apoptosis in vitro. Taken to-
gether, our data suggest that decreased GLO-1 and increased MGO
and AGEs arise in metabolically active plaques, and may contribute to
plaque rupture by inducing apoptosis of macrophages, increasing the
size of the necrotic core.
Methods
An elaborate description of the Methods is provided in the Supplemen-
tary material online.
Athero-express biobank
This study included a random set of 75 plaques from symptomatic (n ¼
62) and asymptomatic (n ¼ 13) patients undergoing carotid endarterec-
tomy (CEA) from the Athero-Express biobank. The study was approved
by the local Ethics Committee and written informed consent was
obtained from all participants. Plaques of the inflammatory and ather-
omatous phenotype, i.e. high macrophages and lipid scores, and with
low smooth muscle cell scores were classified as rupture-prone (n ¼
20). Plaques with a fibrous phenotype, low macrophage, and lipid
scores, and high smooth muscle cell content were characterized as
stable (n ¼ 26). Plaques not falling in either category were classified as
intermediate plaques (n ¼ 29).
Measurement of advanced glycation
endproducts using tandem mass spectrometry
Protein-bound CML, and MGO-derived AGEs N1-(carboxyethyl)lysine
(CEL) and MG-H1 were measured in homogenates of carotid plaques
using ultra performance liquid chromatography tandem mass spectrom-
etry (UPLC-MSMS) by a slightly modified single-run method described
earlier.21 Intra-assay variation for CML, CEL, and MG-H1 was 4.8, 5.0,
and 18.1%, respectively. All samples of the Athero-Express were mea-
sured in a single run, eliminating inter-run variation.
Protein measurements
Plaque cytokines and chemokines (Table 2)weremeasuredbyamultiplex
suspension array system according to the manufacturer’s protocol
(Bender Med Systems). Matrix metalloprotease (MMP)-2, MMP-8, and
MMP-9 activities were measured using the Biotrak activity assays
(Amersham Biosciences).
IL-8, MCP-1, and MMP-9 in cell-culture supernatant were measured
using Meso Scale Discovery (Gaithersburg, USA) multispot human cyto-
kine assays for tissue cultures according to manufacturer’s instructions.
Immunohistochemistry
A random set of 40 plaques from the Athero-Express was selected for
immuno-histological analysis. Consecutive sections were stained with a
mouse monoclonal antibody anti-MG-H1 (1:50.000) and anti-CML
(1:4000).11 Horseradish peroxidase-antimouse IgG (Immunologic) was
used as a secondary antibody.
In addition, stainings were performed with anti-CD68 (1:500, Sigma),
GLO-1 (1:2000), and cleaved caspase-3 (1:100, Cell signaling) on
carotid plaques, obtained from CEA, from the biobank of the Cardiovas-
cular Research Institute of Maastricht (CARIM), Maastricht University.
Staining for hypoxia (mouse anti-pimonidazole 1:50, hypoxyprobe,
NPI)) and oxidative stress (mouse anti-nitrotyrosine 1:500, Calbiochem,
San Diego, USA) were performed on slides of carotid arteries obtained
from 13 patients, infused with pimonidazole prior to CEA.5
CARIM biobank (transcript and protein
analysis of GLO-1 and RAGE)
An intra-plaque comparison approach consisting of CEA atherosclerotic
plaque samples that were selected from the CARIM biobank at Maas-
tricht University, the Netherlands, for transcript and protein analysis
was used to compare GLO-1 and RAGE mRNA and protein between
ruptured and stable plaque segments (n ¼ 26).
GLO-I activitywasassayedbyspectrophotometry (Synergy,Biotek)by
monitoring the increase in absorbance at 240 nm due to the formation of
S-D-lactoylglutathione for 10 min at 378C according to the method of
McLellan and Thornalley,22 in homogenates of stable plaques (n ¼ 4)
and plaques with an intra-plaque haemorrhage (n ¼ 6).
In vitro experiments
Human U937 monocytes (ATCC) were cultured in RPMI 1640 with glu-
tamax (GIBCO), with 1% penicillin and streptomycin (GIBCO) and 10%
foetal calf serum. Cells were cultured for 24 h in 0% oxygen and 48 h in
0.2% oxygen. To study hyperglycaemia, cells were cultured for 14 days
in high glucose (30 mmol/L), or mannitol, as an osmotic control.
Cells were stimulated in serum-free culture medium with 0.2% bovine
serum albumin, and exposed for 24 h to tumour necrosis factor (TNF,
Sigma) (100 U/mL),aminoguanidine (Sigma) (250mmol/l),N-acetylcysteine
(NAC, Sigma) (1 mmol/L), H2O2 (1 or 10 mmol/L), and/or to MGO
(Sigma) (0.1 mmol/L, 0.2 and 0.4 mmol/L). Next, U937 monocytes were
exposed for 24 h to human serum albumin (HSA, 33 mg/mL) and
CML-modified HSA. U937 monocytes were transfected with siRNA
against GLO-1 (Ambion) with AMAXA nucleofector kit C (Lonza) byelec-
troporation, according to the manufacturer’s protocol. Apoptosis was
assessed by flow cytometry (FACS) using annexin-V and 7-AAD following
the manufacturer’s instructions (BD Pharmingen). Cell viability was
assessed by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT; Invitrogen) assay. GLO-1 mRNA expression was assayed
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by qPCR. CML and MG-H1 were quantified in cell lysate with western blot.
b-Actin was used as a loading control.
Murine macrophages
Bone marrow-derived murine macrophages were obtained by differenti-
ating femoral and tibial bone marrow suspensions as described previous-
ly.23 Bone marrow was isolated from 10-week-old C57BL6 mice (JAXw
Mice). Experiments were performed according to Dutch laws, approved
by the Committee for Animal Welfare of Maastricht University. At Day 9,
the macrophages were plated in OptiMEM (GIBCO) and incubated with
or without mouse TNF (Peprotech, 500 U/mL) and MGO (0.1 mmol,
0.2 mmol/L, and 0.4 mmol/L) for 24 h. Cell death (SubG1 peak) and pro-
liferation (S and G2M peak) was assessed by FACS using Propidium–
Iodine, following the manufacturer’s instructions (BD cycletest).
MGO and glyoxal
Secretion of MGO, as well as glyoxal (GO) in culture medium were mea-
sured with UPLC-MSMS.24 Inter-assay variations for MGO and GO were
7.3 and 14.3%, respectively. Intra-assay variations for MGO and GO were
2.9 and 4.3% respectively.
Data analysis
Patient characteristics were expressed as absolute and relative frequen-
cies, as mean with standard deviation, or as median with interquartile
range, when appropriate. Increases in patient characteristics per plaque
category were tested for trend, using analysis of variance (ANOVA) or
x2, as appropriate. Next, associations between plaque AGE levels and
categories of plaque phenotype and inflammatory markers were
assessed with analysis of co-variance (ANCOVA) and linear regression,
respectively, adjusting for sex, age, smoking, and presence of diabetes,
to rule out potential confounding by these factors. Skewed variables
were log-transformed prior to all analyses. Results from in vitro experi-
ments were presented as mean with standard error, and statistical signifi-
cance of the difference between two groups was tested by Student’s
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 General characteristics of individuals, stratified according to plaque phenotype, from the Athero-Express study
(n 5 75)
Patient characteristics Plaque phenotype
Stable (n 5 26) Intermediary (n 5 29) Rupture-prone (n 5 20) P-value
Age, years 67+9 68+9 69+8 0.44
Sex (male), % 69.2 72.4 75.0 0.67
Smoking, % 26.9 37.0 15.8 0.49
Systolic blood pressure, mmHg 160+24 150+32 160+25 0.97
Diastolic blood pressure, mmHg 83+15 81+13 85+14 0.67
History of hypertension, % 73.1 75.9 55.0 0.22
eGFR, mL/min/1.73 m2 71.6+20.8 70.4+25.6 64.1+16.8 0.25
C-reactive protein, mg/L 2.1 (0.9–4.5) 6.1 (3.0–11.4) 5.2 (0.6–6.4) 0.59
Plasma glucose, mmol/L 6.4+2.1 6.5+2.6 7.7+2.21 0.15
History of diabetes, % 53.8 51.7 50.0 0.80
Insulin use, % 23.1 24.1 15.0 0.54
Glucose-lowering medication, % 42.3% 37.1% 45% 0.89
Body mass index, kg/m2 26.3+3.2 28.2+4.9 27.4+4.2 0.39
History of hypercholesterolaemia, % 73.1 89.7 50.0 0.13
Total cholesterol, mmol/L 4.4+0.9 5.1+1.9 4.7+1.0 0.71
High-density lipoprotein, mmol/L 1.2+0.4 1.2+0.3 1.2+0.4 0.88
Low-density lipoprotein, mmol/L 2.4+0.7 3.2+1.7 2.8+0.7 0.53
Triglycerides, mmol/L 1.9 (0.9–2.6) 1.3 (1.1–2.3) 1.4 (1.0–2.1) 0.44
Statin use, % 92.3 82.8 80.0 0.23
Transient ischaemic attack, % 26.9 34.5 50.0 0.11
Minor stroke, % 15.4 24.1 10.0 0.68
Stroke, % 3.8 6.9 5.0 0.84
Amaurosis fugax, % 26.9 20.7 5.0 0.06
Retinal infarction, % 0 0 5.0 0.16
Atypical symptoms, % 3.8 3.4 5.0 0.86
Plaque AGEs
CML, nmol/mmol lysine 70.85 (58.78–88.92) 92.30 (65.55–140.05) 126.35 (62.40–211.08) <0.02
CEL, nmol/mmol lysine 90.50 (79.98–103.15) 91.00 (73.20–110.0) 98.50 (87.40–109.38) 0.15
MG-H1, nmol/mmol lysine 320.35 (272.72–431.30) 392.00 (297.95–841.50) 524.70 (346.35–965.70) <0.01
Data expressed as mean+ standard deviation, as percentage, or as median and interquartile range, as appropriate. Statistical testing wasperformed for trend, using one-way ANOVA,
or x2 test, as appropriate. Skewed variables were log-transformed prior to analyses.
AGE, advanced glycation endproduct.
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AGE MG-H1 plaque levels are higher in
rupture-prone plaques
We first investigated whether plaque MGO-derived AGE levels are
associated with a rupture-prone phenotype in human carotid
plaques. The clinical characteristics of the included patients are
shown in Table 1.
Significantly higher concentrations of CML and MG-H1, but not
CEL, were observed in rupture-prone plaques (Table 1), even after ad-
justment for sex, age, smoking, and presence of diabetes (Figure 1).
Additionally, higher MG-H1 concentrations were observed with in-
creasing percentage of plaque lipid content (Supplementary material
online, Figure S1A), and a similar trend was observed for CML (Supple-
mentary material online, Figure S1B). In line, higher MG-H1 levels were
observed in atheromatous lesions compared with fibrous lesion types
(Supplementary material online, Figure S1A). Interestingly, no increase
of plaque AGEs were observed in patients with diabetes (n ¼ 39)
when compared with non-diabetic patients (n ¼ 36) for CML [79.0
(58.6–126.3) vs. 90.6 (65.6–150.1) nmol/mmol lysine, P ¼ 0.23],
CEL [89.2 (82.0–106.9) vs. 93.4 (75.7–109.0) nmol/mmol lysine,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Associations between plaque advanced glycation endproducts and plaque interleukins and matrix
metalloproteinases
CML CEL MG-H1
b 95% CI for b P-value b 95% CI for b P-value b 95% CI for b P-value
IL-8 0.307 0.077–0.537 ,0.05 0.118 20.128–0.364 0.34 0.295 0.047–0.544 ,0.05
MCP-1 0.240 20.27–0.506 0.08 0.275 0.001–0.548 ,0.05 0.314 0.041–0.588 ,0.05
MMP-9 0.421 0.196–0.647 ,0.05 0.290 0.052–0.528 ,0.05 0.409 0.173–0.646 ,0.05
IL-6 0.142 20.105–0.388 0.26 20.021 20.275–0.234 0.87 0.158 20.105–0.421 0.24
RANTES 0.088 20.222–0.397 0.57 0.314 20.011–0.638 0.06 0.230 20.104–0.564 0.17
PARC 20.023 20.289–0.224 0.80 0.178 20.084–0.440 0.18 0.114 20.152–0.380 0.39
TARC 20.079 20.341–0.182 0.55 0.057 20.213–0.328 0.67 0.025 20.249–0.298 0.18
OPG 20.045 20.644–0.553 0.88 0.711 0.118–1.305 ,0.05 0.319 20.300–0.938 0.31
sICAM 20.029 20.291–0.232 0.82 0.042 20.227–0.311 0.76 20.032 20.305–0.241 0.82
MMP-2 20.014 20.272–0.244 0.91 0.254 0.003–0.506 ,0.05 0.117 20.148–0.383 0.38
MMP-8 0.157 20.089–0.403 0.21 0.223 20.020–0.466 0.07 0.198 20.055–0.451 0.12
The table shows associations between plaque levels of CML, CEL, and MG-H1 with IL-8: interleukin 8, MCP-1, monocyte chemotactic protein-1; MMP-9, matrix metalloproteinase-9;
IL-6, interleukin 6; RANTES, regulatedon activation, normal t expressed and secreted; PARC, pulmonary and activation-regulated chemokine; TARC, thymus and activation-regulated
chemokine; OPG, osteoprotegerin; sICAM, soluble inter-cellular adhesion molecule; MMP-2, matrix metalloproteinase-2; MMP-8, matrix metalloproteinase-8.
Data were analysed using linear regression, all skewed variables were log-transformed prior to analysis and adjusted for age, sex, smoking, and presence of diabetes. The plaque AGEs
were the dependent variable. b indicates 1 standard deviation increase of log-transformed AGE per 1 standard deviation increase log-transformed inflammatory marker.
Figure 1 CML and MG-H1 levels are higher in plaques with an intermediary and rupture prone phenotype. Concentrations of CML (A), CEL (B),
and MG-H1 (C ) were measured with UPLC-MSMS in homogenates of atherosclerotic carotid plaques from the Athero-Express study with a stable,
intermediary, and rupture-prone phenotype. Data are expressed as geometric mean and 95% confidence interval. Statistical testing was performed
for trend, using ANCOVA. Skewed variables were log-transformed. Analyses were adjusted for age, sex, smoking, and the presence of diabetes.
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P ¼ 0.97], and MG-H1 [367.0 (307.0–866.7) vs. 406.2 (288.2–660.0)
nmol/mmol lysine, P ¼ 0.95]. In line, we also found no correlation
between plaque levels of CML (rSpearman¼ 20.118, P ¼ 0.40), CEL
(rSpearman ¼ 20.238, P ¼ 0.09), and MG-H1 (rSpearman ¼ 20.129,
P ¼ 0.36) with plasma glucose levels. These results did not change
when we adjusted for insulin-use and/or glucose-lowering medication
in a linear regression analyses.
CML, CEL, and methylglyoxal-derived
AGE MG-H1 plaque levels are associated
with markers of plaque inflammation
Since AGEs accumulate in the areas of inflammatory activation in ath-
erosclerotic lesions,25 we investigated the associations between
plaque AGE levels and plaque inflammatory markers. CML, CEL,
and MG-H1 were positively associated with MMP-9 (Table 2). Fur-
thermore, CEL and MG-H1 were positively associated with MCP-1
(Table 2), and this was borderline significant for CML. In addition,
CML and MG-H1 were associated with IL-8 (Table 2). Furthermore,
CEL was associated with OPG and MMP-2 (Table 2).
CML and methylglyoxal-derived AGE MG-
H1 accumulate in apoptotic and hypoxic
macrophages
Staining for CML and MG-H1 was observed predominantly in macro-
phages (Figure 2, CD68 positive cells; black arrows) surrounding the
necrotic core (Figure 2, asterisk). In addition, these macrophages
were also positive for the apoptotic marker cleaved caspase-3
(Figures 2 and 3), suggesting that MGO-derived AGEs play a role in
the association between plaque inflammation and necrotic core for-
mation. Furthermore, in consecutive sections, MG-H1 and CML also
co-localized with hypoxia (pimonidazole) (Figure 3), which is particu-
larly associated with the presence of macrophages, inflammation, and
apoptosis. We also observed co-localization between CML, MG-H1,
and the oxidative stress markernitrotyrosine (Supplementary mater-
ial online, Figure S2), but unlike caspase-3 and pimonidazole, we also
encountered areas where only nitrotyrosine, but not CML or
MG-H1, was accumulated. In addition to macrophages, endothelial
cells often stained positive for CML (Figures 2 and 3, white arrows)
and for MG-H1 (Figures 2 and 3, white arrows).
Glyoxalase-1 mRNA and protein level,
but not receptor for advanced glycation
endproducts mRNA, are lower in ruptured
plaque areas
Underlining the importance of GLO-1 in maintaining cell-viability,
GLO-1 staining was abundantly present in the cytoplasm of virtually
all cells of the plaque (Figure 2), but not in the necrotic core. More-
over, micro-array data demonstrated that GLO-1 mRNA was signifi-
cantly lower in ruptured plaque-segments when compared with
stable plaque-segments (ratio ruptured/stable ¼ 0.874; P , 0.01).
In addition, GLO-1 protein levels were decreased to a similar
extent in ruptured compared with stable segments (ratio ruptured/
stable ¼ 0.871), although this was not statistically significant. The
same was true when we measured GLO-1 activity in homogenates
of stable and ruptured plaques (ratio ruptured/stable ¼ 0.613). In
contrast to GLO-1, we found no differences in RAGE expression
between stable and ruptured plaque segments (ratio ruptured/
stable ¼ 0.994; P ¼ 0.53)
Figure 2 CML and MG-H1 co-localization with macrophages
(CD68), and apoptosis (cleaved caspase-3). HE stainings and immu-
nohistochemical detection of CD 68, GLO-1, CML, MG-H1, and
cleaved caspase-3 were performed in CEA specimens. The
HE-staining shows an extensive macrophage infiltration surround-
ing a large intra-plaque haemorrhage (hashtag) in the necrotic
core (asterisk). CML and MG-H1 accumulated predominantly in
macrophages (CD68), especially in apopototic macrophages
(cleaved caspase-3) surrounding the necrotic core. Black arrows in-
dicate macrophages, white arrows indicate plaque vessels. The
square indicates zoomed areas.
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Hypoxia and tumour necrosis factor
decrease glyoxalase I activity and increase
advanced glycation endproduct precursors
Since CML and MG-H1 co-localized with macrophage-rich and
hypoxic regions, and we found decreased GLO-1 expression and ac-
tivity in ruptured plaques, we investigated in U937 monocytes
whether hypoxia and inflammation can decrease GLO-1 activity
and induce formation of the major AGE precursors (in particular
MGO).
We first investigated whether hypoxia contributed to accumula-
tion of AGEs. U937 monocytes cultured in 0.2% O2 induced a reduc-
tion of GLO-1 activity (Figure 4A) and increased MGO (Figure 4B) and
GO (Figure 4C) levels. This effect was much stronger when the cells
were cultured in 0% O2 (Supplementary material online, Figure S3).
Next, activation of cells with the pro-inflammatory cytokine TNF
decreased GLO-1 activity (Figure 4D), accompanied by increased for-
mation of MGO (Figure 4E), and the AGEs MG-H1 (Figure 4G and H )
and CML (Figure 4I and J ), as well as IL-8 (Figure 4K), MCP-1 (Figure 4L),
and MMP-9 (Figure 4M). Similarly, GLO-1 activity was also reduced
(Supplementary material online, Figure S4A), and MGO increased
(Supplementary material online, Figure S4B), when we stimulated
murine macrophages with TNF.
The TNF-induced accumulation of AGEs in U937 monocytes was
not dependent on oxidative stress, as co-incubation with NAC did
not restore GLO-1 activity or reduce MGO or CML (Supplementary
material online, Figure S5). However, incubation of U937 monocytes
with H2O2 strongly increased CML (Supplementary material online,
Figure S6), suggesting that high levels of oxidative stress may act as an
independent source of AGEs. In line with the Athero-Express, high
glucose did not significantly influence GLO-1 activity, MGO, or
AGE levels in U937 monocytes (Supplementary material online,
Figure S7).
The inflammatory response of TNFon IL-8, MCP-1, or MMP-9 was
not dependent on AGEs, because the AGE-inhibitor aminoguanidine
lowered MGO and AGEs (data not shown) but did not decrease IL-8
(Figure4K), MCP-1 (Figure4L), orMMP-9 (Figure 4M) secretion. In line,
direct incubation of monocytes with CML or MGO did not increase
the secretion of IL-8 (Figure 4K), MCP-1 (Figure 4L), or MMP-9
(Figure 4M).
Methylglyoxal induces apoptosis
Since MG-H1 and CML predominantly accumulated in apoptotic
macrophages around the necrotic core, and major AGE precursor
MGO is associated with inducing apoptosis,18,19 we investigated
the effect of MGO on U937 cell-viability. MGO induced formation
of MG-H1(Supplementary material online, Figure S8A and B), and to
a lesser extent CML (Supplementary material online, Figure S8C
and D) as well as adose-dependent increase in AAD-7 andAnnexin-V
double positive cells, indicating apoptotic cells (Figure 5A–C). In line,
MGO induced cell-death in murine macrophages (Supplementary
material online, Figure S4F ), but did not decrease proliferation, as
assayed with propidium–iodine (S-peak and G2/M peak) (Supple-
mentary material online, Figure S4G and H ).
We next investigated whether decreased GLO-1, as found in the
ruptured plaque-segments, reduced cell-viability of U937 mono-
cytes. In untreated cells, siRNA against GLO-1 lowered GLO-1 activ-
ity (Figure 5D) and mRNA expression (Figure 5E), but did not increase
endogenousMGO production (Figure5F) and cell viability (Figure 5G).
However, when challenged with MGO, the transfected cells dis-
played decreased MGO-induced cell viability compared with the
scrambled-treated cells (Figure 5H and I ), demonstrating that
GLO-1 is important to protect cells from the cytotoxic effects of
MGO.
Discussion
Our study shows for the first time that the plaque concentrations of
the specific AGEs CML and MG-H1 areassociated with inflammatory
plaquemarkers andwerehigher in rupture-proneplaques (i.e. inflam-
matory atheromatous lesions). CML and MG-H1 predominantly
localized in macrophages surrounding the necrotic core, and were
associated with apoptosis and hypoxia. In ruptured plaque segments,
GLO-1 mRNA and protein concentrations were reduced. In U937
monocytes, TNF and hypoxia decreased GLO-1 activity and
Figure3 CML and MG-H1 co-localize with hypoxic regions. Plaques of patients infused with hypoxia markerpimonidazolewere stained for pimo-
nidazole, cleaved caspase-3, CML, and MG-H1. We observed a striking co-localization between hypoxia (pimonidazole), CML, MG-H1, and apop-
tosis (cleaved caspase-3). Black arrows indicate macrophages, white arrows indicate plaque vessels. The square indicates zoomed area.
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increased the production of the AGE precursor MGO. MGO
induced AGE formation and caused apoptosis, which was enhanced
by GLO-1 knock-down, providing functional evidence for the in-
volvement of GLO-1 in MGO-mediated apoptosis. Taken together,
these results suggest that the increase of AGEs and consequences
thereof for macrophage cell death may contribute to the transition
of stable to rupture-prone plaques.
To our knowledge, this is the first study in which specific AGEs
were quantified in homogenates of atherosclerotic plaques using
UPLC-MSMS.Several studieshave shownwith immunohistochemistry
that AGEs accumulate in atherosclerotic lesions of the aorta,8,26,27
coronary9 and carotid arteries using antibodies against CML
or glycation-modified proteins. In accordance with previous
studies,25,26,28,29 we identified the macrophage as the major site for
AGE accumulation in the plaque.
Advanced glycation endproducts can be derived from several
pathways in atherosclerotic lesions. Previous work from our group
has demonstrated the importance GLO-1 as a critical defense line
against glycation in vivo.30 We hypothesized that inflammation and
hypoxia in atherosclerotic plaques contribute to increased concen-
trations of AGEs by decreased GLO-1 expression. Indeed, in U937
monocytes TNF, a strong pro-inflammatory stimulus, as well as
hypoxia, decreased GLO-1 activity, accompanied by increased
MGO production. Importantly, we found similar effects of TNF on
Figure 4 Hypoxia and tumour necrosis factor inhibit GLO-1 activity and induce MGO in U937 monocytes. U937 cells were cultured under
hypoxic conditions (0.2% O2) for 48 h or with tumour necrosis factor (100 U/mL) for 24 h. GLO-1 activity (A and D) was measured. MGO (B
and E) and GO (C and F) were measured in the culture supernatant with UPLC-MSMS. MG-H1 (G, quantification H ) and CML (I, quantification
J ) were measured with western-blot in the cell-lysate. b-actin was used as a loading control. U937 monocytes were treated with tumour necrosis
factor, aminoguanidine (AG), MGO, and HSA-CML, and protein levels of IL-8 (K ), MCP-1 (L), and MMP-9 (M) were measured in the supernatant.
Data are presented as mean and standard error. Differences were tested with Student’s t-test for two independent samples.
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GLO-1 and MGO in murine macrophages. In line with a previous
report,31 high glucose did not materially contribute to accumulation
of AGEs in U937 monocytes.
One of the hallmarks of rupture-prone plaques is a large necrotic
core. In humancarotidplaques, CML andMG-H1 werepredominant-
ly present in caspase-3 positive macrophages surrounding necrotic
regions of the plaque. Furthermore, MGO induced cell-death in
monocytes and murine macrophages, a finding which is consistent
with previously reported data.18,19 We hypothesize that this may
lead to a vicious cycle of inflammation, increased formation of
MGO (and AGEs), inducing apoptosis of macrophages, growth of
necrotic core, up to the point that plaque rupture occurs. This
process may be aggravated by hypoxia and oxidative stress. We
showed the importance of GLO-1 in protecting cells against toxic
effects of MGO by showing decreased viability of U937 monocytes
after GLO-1 knockdown. Therefore, our current work suggests
that GLO-1 may protect against plaque rupture. To support this
notion, we found decreased expression of GLO-1 in ruptured vs.
stable plaque segments. We hypothesize that interventions aimed
at restoring the glyoxalase pathway and/or reducing MGO levels in
the plaque, will reduce glycation, and subsequently will reduce cell-
death and necrotic core size. Future studies are needed to evaluate
this concept in vivo.
Advanced glycation endproducts such as CML and MG-H1 may be
more than mere markers of protein damage by MGO. Many studies
have shown the importance of the receptor for AGEs (RAGE) in the
progression of atherosclerosis.25,32 In plaques, RAGE is present on
macrophages25 and endothelial cells.32 Furthermore, it has been
demonstrated that extracellular activation of RAGE by AGEs triggers
NF-kB signalling.33 Therefore, the increased AGEs we observed in
rupture-prone plaques may be important ligands for RAGE in vivo,
contributing to a vicious cycle between plaque inflammation and
AGE accumulation. However, the data from the current study
suggest that the formation of AGEs seem to be a consequence, and
not a cause of the pro-inflammatory status, because AGEs did not
mediate TNF-induced secretion of inflammatory markers, nor
directly induced inflammatory markers. Since we did not find
any up-regulation of RAGE in ruptured plaque segments, the
Figure 5 GLO-1 knockdown reduces viability after incubation with MGO in U937 monocytes. U937 cells were incubated for 24 h with 0.1, 0.2,
0.3, and 0.4 mM MGO, and apoptosis was assessed by flowcytometric analyses for Annexin-V and 7-AAD (A, control; B, 0.4 mmol/L MGO, quan-
tification in C). Statistical testing was performed for trend, using ANOVA. Next, U937 cells were transfected with siRNA against GLO-1, and GLO-1
activity (D) and mRNA (E) were measured. MGO (F) was measured with UPLC-MSMS in the culture supernatant. Next, cells were incubated with
MGO for 24 h and viability wasmeasuredby an MTT assay (G, 0 mmol/L MGO; H, 0.2 mmol/L MGO; and I, 0.4 mmol/L MGO). Data are presented as
mean and standard error. Differences were tested with Student’s t-test for two independent samples.
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AGE–RAGE interactions may be of lesser importance than intracel-
lular accumulation of AGEs and subsequent cell-death in plaque
rupture in human atherosclerosis. These findings are provocative,
and deserve further research. In addition, AGEs may contribute to
the development of atherosclerosis via the formation of extracellular
cross-linking of proteins, as AGE-crosslink breaker ALT-711 attenu-
ates diabetic atherosclerosis in ApoE knock-out mice.13 Further-
more, induction of oxidative stress by MGO30 may also contribute
to predisposition towards plaque-rupture, as MGO and ROS forma-
tion are closely intertwined,34 and it has been shown that MGO
induces apoptosis in an ROS-dependent manner.35
Our study has some limitations. First of all, by the cross-sectional
design of this study, it is impossible to investigate whether accumula-
tion of AGEs precedes development of rupture-prone lesions. More-
over, in the plaques of the Athero-express study, we defined
inflammatory atheroma’s as rupture-prone plaques, as these
plaques have a similar phenotype as ruptured plaques. We cannot de-
termine in this study if these plaques indeed have the highest risk of
plaque rupture, although the finding of higher plaque AGEs in
rupture-prone plaques is consistent with the decreased GLO-1 in
the ruptured plaques of the CARIM biobank. Furthermore, we
cannot exclude residual confounding in the associations between
plaque AGEs and plaque phenotype, as data on potential confoun-
ders were either not determined in this study (such as Hba1c), or
missing in a high proportion of participants (plasma lipids). We
found no increase of plaque AGEs in individuals with diabetes. This
finding should be interpreted with caution, as we did not measure
HbA1c, and 41% of individuals with diabetes used insulin, and
79.5% used oral glucose lowering medication. However, when we
adjustedouranalyses for insulin andoral glucose loweringmedication
our results were similar.
Taken together, our study supplies unique data, showing an asso-
ciation between human plaque concentrations of specific MGO-
derived AGEs and GLO-1, cell-death, and plaque phenotype. The gly-
cation pathway may be a major player in the progression of stable to
rupture-prone plaques and subsequent plaque rupture. Future
studies should focus on a causal relationship between AGEs, MGO,
and plaque phenotype.
Supplementary material
Supplementary material is available at European Heart Journal online.
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